Try our Advanced Search for more refined results

February 05, 2021

UCB, Inc. et al v. Catalent Pharma Solutions Inc. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. November 29, 2021

    Catalent Can't Duck IP Suit Over Epilepsy Drug Vimpat

    A Kentucky federal judge on Monday denied a bid to dismiss UCB’s suit against Catalent Pharma Solutions over its importation of the active ingredient in anti-epileptic drug Vimpat, saying the complaint plausibly alleges infringement.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!